They stated that skin and circulating levels of the anti-inflammatory IL-38 are reduced in psoriasis patients and the treatment with Secukinumab causes its upregulation and, subsequently, correlates with therapeutic efficacy [11]. This evidence concerns the gene IL1F10 and psoriasis.